As of Friday close, Sana Biotechnology Inc.’s (NASDAQ:SANA) stock was up $0.82, moving up 11.07 percent to $8.23. The average number of shares traded per day over the past five days has been 1,466,800 shares. 4 times new highs have been achieved over the past 5 days, with a $1.55 gain in that time frame. In the last twenty days, the average volume was 1,242,035, while in the previous 50 days, it was 1,526,382.
Since last month, SANA stock retreated -1.20%. Shares of the company fell to $5.84 on 08/02/22, the lowest level in the past month. A 52-week high of $26.60 was reached on 01/03/22 after having rallying from a 52-week low of $3.92. Since the beginning of this year, SANA’s stock price has dropped by -46.83% or -$7.25, and marked a new high 1 time. However, the stock has declined by -69.06% since its 52-week high.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Sana Biotechnology Inc. (SANA) last reported insider trading activity 138 days ago on Mar 21. Yang Patrick Y, the Director of the company, purchased of 28,000 shares for $7.30 on Mar 21. It resulted in a $204,400 investment by the insider. MacDonald James J. sold 333 shares at an average price of $6.28 on Feb 18. The insider now owns 429,417 shares following the transaction. On Sep 16, EVP, Head of Development & CMO AGARWAL SUNIL sold 1,627 shares at $26.00 apiece. The transaction was valued at $42,302.
In the three months ended March 30, Sana Biotechnology Inc.’s quick ratio stood at 5.60, while its current ratio was 5.60, showing that the company is able to pay off its debt. Based on annual data, SANA earned $0.98 million in gross profit and brought in $356.91 million in revenue.
While analysts expected Sana Biotechnology Inc. to report -$0.47 quarterly earnings, the actual figure was -$0.17 per share, beating the consensus estimate by 63.80%. The liabilities of Sana Biotechnology Inc. were 331.58 million at the end of its most recent quarter ended March 30, and its total debt was $112.15 million. The value of shareholders’ equity is $190.23 million.
This quick technical analysis looks at Sana Biotechnology Inc.’s (SANA) price momentum. With a historical volatility rate of 120.09%, the RSI 9-day stood at 61.49% on 05 August.
With respect to its five-day moving average, the current Sana Biotechnology Inc. price is up by +23.20% percent or $1.55. At present, SANA shares trade -6.80% below its 20-day simple moving average and +55.87% percent above its 100-day simple moving average. However, the stock is currently trading approximately +94.10% above its SMA50 and -58.77% below its SMA200.
Stochastic coefficient K was 43.58% and Stochastic coefficient D was 26.70%, while ATR was 0.81. Given the Stochastic reading of 64.42% for the 14-day period, the RSI (14) reading has been calculated as 58.55%. As of today, the MACD Oscillator reading stands at 0.34, while the 14-day reading stands at -0.08.
Morgan Stanley launched its rating on Sana Biotechnology Inc. (NASDAQ: SANA) to an Overweight in a note to investors on March 01, 2021. Sana Biotechnology Inc. (SANA) has been rated Overweight by analysts. According to 0 brokerage firms, SANA is a sell, and 2 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Sana Biotechnology Inc. stock as buy, with 2 recommending it as overweight.
With a median target price of $13.00, the current consensus forecast for the stock is $7.00 – $15.00. Based on these forecasts, analysts predict Sana Biotechnology Inc. (SANA) will achieve an average price target of $12.00.